PaxVax Gets $2M For Oral Flu Vaccines

San Diego-based PaxVax, a firm working on orally-administered flu vaccines, has raised $2.0M out of a $6.0M funding round, according to a filing last week. Investors in the new round include Ignition Partners. According to Paxvax, its oral tablets can be stored and distributed at room temperature, and can be produced in large quantities and at low expense compared to traditional flu vaccines. The firm is headed by Kenneth Kelley, who has previously been at IntraBiotics, Integrated Genetics, K2 BioVentures, Latterell Venture Partners, Institutional Venture Partners, and McKinsey & Company.